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2212-0661/© 2016 The Authors. Published by Elsevier B.Va b s t r a c ta r t i c l e i n f oKeywords: Background: The conduct of international collaborative genomics research raises distinct ethical challenges that
require special consideration, especially if conducted in settings that are research-naïve or resource-limited. Al-Ethics
though there is considerable literature on these issues, there is a dearth of literature chronicling approaches taken
to address these issues in the ﬁeld. Additionally no previous ethical guidelines have been developed to support
similar research in Trinidad and Tobago.
Methods: A literature review was undertaken to identify strategies used to address common ethical issues rele-
vant to human genetics and genomics research in research-naïve or resource-limited settings. Strategies identi-
ﬁed were combined with novel approaches to develop a culturally appropriate, multifaceted strategy to address
potential challenges in the Genetics Substudy of the National Eye Survey of Trinidad and Tobago (GSNESTT).
Results: Regarding the protection of study participants, we report a decision to exclude children as participants;
the use of a Community Engagement and Sensitization Strategy to increase the genetic literacy of the target pop-
ulation; the involvement of local expertise to ensure cultural sensitivity and to address potential comprehension
barriers in informed consent; and an audit of the informed consent process to ensure valid consent. Concerning
the regulation of the research, we report on ethics approvals from relevant authorities; a Materials Transfer
Agreement to guide sample ownership and export; and a Sample Governance Committee to oversee data use
and data access. Finally regarding the protection of the interests of scientists from the host country, we report
on capacity building efforts to ensure that local scientists have access to data collected through the project and
appropriate recognition of their contributions in future publications.
Conclusion: This paper outlines an ethical framework for the conduct of population-based genetics and genomics
research in Trinidad and Tobago; highlights common issues arising in the ﬁeld and strategies to address these.
© 2016 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Human genomics
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It is well documented that there are a host of ethical issues associat-
ed with the conduct of human genetics and genomics research (HGR).
Typically these issues are related to concerns regarding informed con-
sent, privacy of research participants, return of results and incidental
ﬁndings, data storage and data sharing (de Vries et al., 2011; Kaye
et al., 2010; Wright et al., 2013). Many ethical issues associated withthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Box 1
Description of the National Eye Survey of Trinidad and Tobago
(NESTT).
The National Eye Survey of Trinidad and Tobago (NESTT)
(September 2013–November 2014) was a nationally-representa-
tive, population based epidemiological survey to determine the
prevalence, causes and risk factors for vision loss in the population
aged 5 years and above in Trinidad and Tobago. Randomized mul-
tistage sampling, using probability proportionate to size methods,
was used to select approximately 10,000 individuals in 120 geo-
graphical clusters. Participants had a basic vision assessment
and interview in their communities. Everyone aged 40 years and
above, and those aged 5 to 39 years with vision impairment or di-
abetes mellitus, were invited for comprehensive medical and oph-
thalmic assessment in regional clinics. The clinical examination
included ocular photography, biometry and optical coherence to-
mography of the anterior and posterior segments.
Box 2
Description of the Genetics Substudy of the NESTT (GSNESTT).
The Genetics Substudy of the NESTT (GSNESTT) (August 2014–
June 2015) aimed to create a research database of clinically-well
characterized individuals to investigate genetic and environmental
factors associated with vision loss and blindness in Trinidad and
Tobago, including cardiovascular diseases. The GSNESTT in-
volved the collection of saliva samples from volunteers, aged
18 years old and above,who completed a comprehensive ophthal-
mic and medical assessment in the main NESTT epidemiological
survey. Samples were transported from the field for temporary
storage at the University of the West Indies, and were shipped to
Duke University Biobank in the USA for DNA extraction and stor-
age. Future research utilizing this research database will include
GenomeWide Association Studies.
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collaborations involving research-naïve or resource-limited settings
(de Vries et al., 2011).
In these settings, there is an overall concern about the lack of capac-
ity of the host countries to conduct and lead the research themselves as
well as the lack ofwell-trained ethics review committees and regulatory
agencies (Chanda-Kapata et al., 2015; Roach, 2015). There are also
corresponding concerns about the need for project designs to take
into account cultural beliefs and practices of the host community, the
degree of exposure (and education) of the community with respect to
genetics and the true potential of the project to yield beneﬁts to the
host country (Ramsay et al., 2014; de Vries et al., 2015). Issues related
to the appropriateness of informed consent models, maintaining the
privacy and conﬁdentiality of study participants, and disclosure of ﬁnd-
ings including incidental ﬁndings and obligations to family members
take center stage (McGuire and Beskow, 2010; Kaye et al., 2010;
Ramsay et al., 2014; de Vries et al., 2015; Chanda-Kapata et al., 2015).
Additionally, given the social and economic contexts of many of the
target populations there are underlying concerns about potential stig-
matization and discrimination, especially since most countries lack leg-
islation to protect against this type of harm (WHO, 2002; Foster and
Sharp, 2006). Other key issues in these settings include the sharing of
samples and data across different jurisdictions (Chanda-Kapata et al.,
2015).
These ethical issues have been categorized into three main classes:
protecting the interests of research populations; regulating human ge-
nomics research; and protecting the interests of scientists in the devel-
oping world (de Vries et al., 2011). While the literature contains
extensive discussion of these ethical issues, there are fewer articles
chronicling approaches taken to address these issues in the ﬁeld. Addi-
tionally, articles providing information about the approaches used in
the ﬁeld have been limited to research conducted on the African conti-
nent. There is a paucity of literature speciﬁc to the Caribbean Basin. This
article attempts to bridge this gapby reporting onmeasures taken to ad-
dress key ethical challenges in theGenetics Substudy of theNational Eye
Survey of Trinidad and Tobago (GSNESTT).
1.1. The context and rationale for a National Eye Survey of Trinidad and
Tobago (NESTT)
An estimated 32.4 million people worldwide are blind and 191 mil-
lion are moderately or severely visually impaired (Bourne et al., 2013).
Given the high prevalence of numerous risk factors for eye disease
and vision loss in the population (Chadee et al., 2013; Cawich et al.,
2014; Pan American Health Organisation, 2013), in particular diabetes
mellitus, local eye care professionals and local government thought it
was necessary to gather data on the prevalence, causes and risk factors
of vision loss in Trinidad and Tobago (TT). As such the National Eye Sur-
vey of Trinidad and Tobago (NESTT) was conceptualized (see Box 1).
The aimof the studywas to generate an evidence base to informpolicies
and health service development to reduce the burden of avoidable vi-
sion loss in the population. This study was funded primarily by the
localMinistry of Health (MOH), andwas delivered through an academic
collaboration between the University of theWest Indies (UWI) and An-
glia Ruskin University (ARU) in the United Kingdom.
1.2. The rationale behind the Genetics Substudy of the NESTT (GSNESTT)
In recent years, multiple studies have explored the genetic epidemi-
ology of eye disease and have greatly advanced understanding of how
and why diseases develop in different populations (Li et al., 2015;
Bailey et al., 2016). Given the reportedly high burden of eye disease in
Trinidad and Tobago, coupled with the supporting scientiﬁc literature
highlighting the presence of genetic risk factors in populations with
high burdens of eye disease, the study team felt that the data collected
in the main study would be inadequate to investigate genetic andenvironmental factors contributing to the reportedly high burden of
eye disease in Trinidad and Tobago.
Further considering that themajority of recent studies on the genetic
epidemiology of eye diseases have focused on Caucasian and Asian pop-
ulations, and it was unclear whether the population of TT possessed a
unique set of genetic variants, which might inﬂuence disease suscepti-
bility and the effectiveness of speciﬁc treatments. To address these con-
cerns, the Genetics Substudy of NESTT (GSNESTT) was designed (see
Box 2).
1.3. The rationale for developing an ethical framework for GSNESTT
Trinidad and Tobago (TT) is themost industrialized nation in the Ca-
ribbean,with lowunemployment rates andhigh literacy rates. Itwas re-
moved from the OECD list of developing countries in 2011, and in 2015
the nation was ranked as a “High Income” country by the World Bank.
Despite these positive socioeconomic indicators, several considerations
relating to the sociocultural context of TT made the ethical issues asso-
ciated with the GSNESTT worthy of special attention.
Firstly, the GSNESTT was the ﬁrst genetics/genomics study conduct-
ed in TT that included a nationally-representative population sample.
The stakeholders (academic and government)were therefore conscious
of the fact that this study would impact the landscape for other similar
studies in the country. Speciﬁcally, it was acknowledged that the way
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trust towards genetics or genomics research; that the tools and proce-
dures created for the GSNESTT could serve as a benchmark for similar
studies; and that the knowledge gained from this study could inform
policies to regulate future human genetics research in Trinidad and
Tobago.
Secondly, amajor concernwas the paucity of data on genetic literacy
and attitudes towards genetic and genomic research of the general
population in TT. Therewas also limited data on the capacity of local re-
search ethics committees to adequately evaluate genetics and genomics
research proposals. This meant that cultural nuances that may have af-
fected participant participation in the GSNESTT were unclear and ques-
tions about the capacity of the participants to comprehend the
implications of their participation in the study were raised.
Thirdly, there was an absence of dedicated bioethics (or research
ethics) training programs at the local universities and a lack of legisla-
tion in the country to regulate HGR or use of genetic data. Furthermore,
NESTT planned to transfer genetic data abroad on account of inadequate
capacity for long term secure storage of DNA in country, and a lack of au-
tomated facilities for DNA extraction andwhole genome analysis. Taken
together these raised issues about the ability of TT to protect partici-
pants from possible discrimination as well as regulate the secondary
use of participant data once they left local shores.
A ﬁnal consideration was the fact that the study was funded by the
local government. Stakeholders felt that the use of public funding im-
plied an expectation of direct and immediate beneﬁt to the population.
Thiswas a source ofmajor concern as the teamunderstood that the ben-
eﬁts of GSNESTT may not be immediately apparent. Therefore, at the
outset it was decided that since the study was publicly funded and the
country had more pressing public health concerns, budget allowance
would only be made for the collection of tissue samples. To facilitate
storage and DNA extraction, an academic collaboration was established
with a highly reputed genomics center in the United States at no cost,
and the team agreed that external grants would be sought for genomic
analyses. Also, in light of the logistical issues of collecting blood samples,
saliva was chosen as the preferred source of genetic information.
Given these observations, the team recognized that TT may be con-
sidered research-naive with regard to genetics and genomics research
and therefore it was necessary to build into the GSNESTT mechanisms
to address possible ethical challenges that could be faced in the ﬁeld.
As a result, a review of the literature was conducted to identify strate-
gies and practices commonly employed by other similar studies.
2. Methods
A review of the literature on ethical issues associated with genetics
and genomics research in developing countries, research-naïve or
resource-limited settings published up to October 31, 2013 was con-
ducted using Pubmed (National Library of Medicine). The search was
constructed to identify primary studies and ‘experiences’ on approaches
used to address ethical issues in international collaborative HGR pro-
jects. Articles providing an overview on speciﬁc ethical issues were
accessed as long as they also included practical recommendations.
Thus, although there is a wealth of information on ethical issues related
to genetics and genomics research, many published papers were not
considered relevant for this analysis. Fig. 1 outlines the process of selec-
tion of articles for this literature review. Through this process, eleven
(11) articles of relevance to the development of an ethical framework
in this study were identiﬁed (see Table 1).
The process of data extraction involved a critical review of the select-
ed articles to identify the following information: type of primary study;
ethical issues identiﬁed; strategies and rationale underlying strategies
used to address the ethical challenges. Particular attention was given
to discussions related to issues of informed consent, secondary data
use, transfer of data across borders, and the treatment of incidentalﬁnd-
ings. Using the tripartite classiﬁcation for ethical issues in humangenomics research conducted in less developed countries (de Vries
et al., 2011), the main ethical issues identiﬁed in the literature were
grouped into the following categories: i) protecting the interests of
research populations; ii) regulating human genomics research; and
iii) protecting the interests of scientists in the developing world. The
strategies presented in the articles addressing ethical issues in these
areas were identiﬁed and tabulated (see Table 2).
Using strategies reported from other studies or suggested in the
literature, the study team developed a comprehensive ethical approach
to guide the GSNESTT in the following eight key areas: 1) fair selection
of study participants; 2) community engagement and sensitization;
3) ensuring valid informed consent; 4) assuring the quality of the in-
formedconsentprocess; 5) acquiringnecessary ethics approvals; 6) reg-
ulating the transfer of data across borders; 7) regulating the secondary
use of data; and 8) capacity-building in TT. Finally, the GSNESTT ethical
framework was assessed to ensure adherence to general international
guidelines on the ethical conduct of human subjects' research (see
Table 3).
3. Results
3.1. Developing an ethical framework to guide the GSNESTT
Drawing from all the literature, the following multifaceted strategy
was developed to guide the GSNESTT.
3.1.1. Protecting the interests of research populations
3.1.1.1. Fair selection of study participants. Recruitment for NESTT utilized
multi-stage, randomized, cluster sampling, with probability proportion-
ate to sizemethods. This gave each person aged 5 years and above in the
non-institutionalized population of TT an equal chance of being selected
for inclusion in the study. At the outset, the study team decided that
although participation by children had the potential to offer additional
advances in understanding developmental eye conditions, the
GSNESTTwould not include children as participants. Despite the ethical
approaches presented in the literature informing the inclusion of chil-
dren in HGR (de Vries et al., 2011), the research team recognized that
this would introduce complex ethical issues, particularly with respect
to informed consent.
3.1.1.2. Community engagement and sensitization. Protecting the interests
of research participants through the engagement of the communitywas
paramount. Consistent with the literature, key stakeholders were iden-
tiﬁed and engaged. These included professional societies, advocacy and
patient groups, governmental and non-governmental organizations,
and academic institutions, many of whom had been engaged prior to
the start of the main epidemiological study. Careful consideration was
also taken to develop a Community Engagement and Sensitization
Strategy (CESS) to provide essential guidance for the engagement and
sensitization of stakeholders involved in the GSNESTT.
Under the guidance of the Communications Department in theMin-
istry of Health, an ofﬁcial soft launch was held for the GSNESTT, follow-
ed by amajormedia campaign – both approachesmentioned in Chokshi
et al. (2007). Given the lack of data regarding the genetic literacy of the
population of TT, a key element of the media campaign was to increase
basic education in genetics, and raise awareness about the purpose and
nature of the study. Articles were published in the local newspapers and
the university's newsletter providing basic information on genetic ter-
minologies and concepts, as well as highlighting major ethical issues
in genetics/genomics research (Carrington and Roach, 2014; Roach,
2014). Radio and television interviews were held with key members
of the NESTT research team, in which the study was introduced and
basic information about genetics and genetics/genomics research
discussed in relation to eye disease. Additionally a Facebook page was
used to provide engagement via social media. A scientiﬁc forum on a
Fig. 1. Process of selection of articles for the development of the GSNESTT Framework.
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reduce any fear and mistrust in the scientiﬁc community and general
population.Table 1
Identiﬁed articles including approaches to address ethical challenges associated with genetics
Identiﬁed articles
Caulﬁeld T, McGuire AL, Cho M, et al. Research Ethics Recommendations for Whole-Genom
Consensus Statement. PLoS Biology. 2008;6(3):e73.
Chokshi DA, Parker M, Kwiatkowski DP. Data sharing and intellectual property in a genom
policies for large-scale research collaboration. Bulletin of the World health Organization
Chokshi DA, Thera MA, Parker M, et al. Valid Consent for Genomic Epidemiology in Develo
PLoS Medicine. 2007;4(4):e95.
De Vries J, Bull SJ, Doumbo O, et al. Ethical issues in human genomics research in developi
BMC Medical Ethics. 2011;12:5.
Kaye J, Boddington P, de Vries J, Hawkins N, Melham K. Ethical implications of the use of w
medical research. European Journal of Human Genetics. 2010;18(4):398–403.
McGuire AL, Beskow LM. Informed Consent in Genomics and Genetic research. Annual rev
human genetics. 2010;11:361–381.
McGuire AL, Caulﬁeld T, Cho MK. Research ethics and the challenge of whole-genome sequ
Nature reviews Genetics. 2008;9(2):152–156.
Parker M, Bull SJ, de Vries J, Agbenyega T, Doumbo OK, Kwiatkowski DP (2009) Ethical Da
Genome-Wide Association Studies in Developing Countries. PLoS Med 6(11): e1000143
Staunton C and Moodley K. Challenges in biobank governance in Sub-Saharan Africa. BMC
Tindana P, Bull S, Amenga-Etego L, et al. Seeking consent to genetic and genomic research
A qualitative study of the MalariaGEN experience. BMC Medical Ethics. 2012;13:15.
Wright GE, Koornhof PG, Adeyemo AA, Tifﬁn N. Ethical and legal implications of whole ge
sequencing in African populations. BMC Medical Ethics. 2013;14:21.In line with the reports by de Vries et al. (2011) and Tindana et al.
(2012), the engagement activities were shaped by the characteristics
of the target population. The communities targetedwere highly diverse,and genomics research in developing countries or resourced strapped nations.
Justiﬁcation for inclusion
e Research: Overview with recommendations
ic epidemiology network:
. 2006 May;84(5):382–7.
Practical Experience MalariaGEN
ping Countries. Overview practical experiences various
studies Africa
ng countries. Practical Experience MalariaGEN
hole genome methods in Overview with recommendations
iew of genomics and Overview with recommendations
encing. Overview with recommendations
ta Release in
.
Practical Experience MalariaGEN
Medical Ethics 2013, 14:35. Overview H3Africa
in a rural Ghanaian setting: Practical Experience MalariaGEN
nome and whole exome Practical Experience H3Africa Consortium
Table 2
Approaches used to address ethical issues in genomics research the ﬁeld.
Selected approaches used in the field to address ethical challenges associated with international collaborative genetics and genomics research 
ETHICAL ISSUE APPROACH REFERENCE
A. Protecting the interests of research Participants
1) Fair selection of study participants
i. Issues related to involvement of children Development of specific protocols for children 
eg assess competence on case by case basis
Choksi et al (2007)
de Vries et al (2011)
2) Community Engagement and Sensitization
i. Community Engagement Model of engagement consistent with community processes 
Ad hoc community engagement initiatives
Community Meetings
Community Advisory Groups
Official ceremony
Tindana et al (2012)
de Vries et al (2011)
Tindana et al (2012)
Wright et al (2013)
Choksi et al (2007)
ii. Improvement of genetic literacy/ 
community education in genetics
Tailored to local setting eg videos, 
announcements, audio etc
Choksi et al (2007)
Ensuring valid informed consent
i. Participant comprehension: linguistic 
and cultural barriers
Using local language or culturally relevant 
descriptive to explain complex concepts like 
“genetics” and “genomics”
Choksi et al (2007)
de Vries et al (2011)
Wright et al (2013)
Tindana et al (2012)
McGuire et al (2008) 
ii. Informing participant about complex 
issues, eg: potential loss of identity, 
incidental findings and group 
stigmatization
Collaborative approach towards development of 
informed consent document. 
Candid discussion in consenting process and 
Inclusion in consent form
Need for legislation/relevant guiding policy e.g. 
return of results policy
de Vries et al (2011)
Choksi et al (2007) 
Caufield et al (2008)
Wright et al (2013)
Tindana et al (2012)
McGuire et al 
(2010)
McGuire et al 
(2008)
Kaye et al (2010)
Wright et al (2013)
iii. Challenges in administering consent Training of field workers and discussion of 
possible different scenarios eg emergency 
situations
de Vries et al (2011)
Tindana et al (2012)
iv. Reducing inducement that may arise 
from offering medical care
Repeat during study (and assess) that provision 
of care is not contingent on participation
Choksi et al (2007)
Assuring the quality of the informed consent process
i. Ensuring validity/assuring quality of consent Assessments in the field Tindana et al (2012)
B. Regulating human genomics research
Regulating the transfer of samples and data across borders
i. Cross border data issuesrelating to Eg  
transfer of samples and privacy and 
confidentiality of data
Use of a Materials Transfer Agreement
Need to establish legislation/policy
de Vries et al (2011)
Wright et al (2013)
Staunton et al (2013)
McGuire et al (2008) 
Caufield et al (2008)
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Regulating the secondary use of samples and data
ii. Secondary use of samples in a manner 
consistent with participants’ consent 
(data access) or sharing of data in 
general for research purposes
Governance Structure eg. Data Access 
Committee or data sharing/access policy
Mechanism to facilitate communicat ion/data 
release between researchers and participants eg online 
Certificates of Confidentiality 
Choksi et al (2006)
Parker et al  (2009) 
Caufield et al (2008)
Wright et al (2013)
Kaye et al (2010)
McGuire et al 
(2010) 
McGuire et al 
(2010) 
Acquiring necessary ethics Approvals
iii. Ethics review Ethics approvals from all partners Caufield et al (2008)
de Vries et al (2011)
Wright et al (2013)
C. Capacity building of local community
Capacity building in TT
Building capacity of local researchers Training of local researchers in analysis of 
genomic data
Workshops for local RECs/IRBs
Development of a software to allow for remote 
analysis of genomic data
PhD. Studentship to investigate ethical issues
Policies/relationships guiding how data is released 
de Vries et al (2011)
Wright et al (2013)
de Vries et al (2011)
de Vries et al (2011)
Choksi et al (2006)
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signs and extensive postal systems that were easily accessible, to ex-
tremely rural and highly impoverished areas, with houses that were
not present on town maps, a corresponding post system that was not
as structured, and terrain that at timeswas accessible only via footpaths.
As a result, a more personal, labor and resource intensive strategy of
participant engagement was devised. Further, based on the premise
that informed consent starts at the ﬁrst moment of contact with poten-
tial participants, participant engagement strategies were designed to
uphold the voluntariness of informed consent aswell as reduce any pos-
sibility of undue inﬂuence.
All potential target areas were assessed individually and engage-
ment protocols were reviewed and tailored to suit the speciﬁc commu-
nity. Some people were recruited at the time they attended clinic for
their eye exam, and under these circumstances carewas taken to ensure
that the participants did not feel pressure to participate (Chokshi et al.,
2007). Amajority of participantswere recontacted afterwards and invit-
ed to participate in the GSNESTT. The method for recontact involved
using a telephone script as a guide, and calling each potential partici-
pant. Once potential participants indicated that they were not interest-
ed in learning more about the study, they were not contacted again.
Following telephone contact, the team visited communities wearing
NESTT uniforms and a blow horn was used to announce the days that
the study team would be visiting. A brochure which outlined the pur-
pose of the Genetics substudy, the risks and beneﬁts, and proceduresinvolved, was left with each household and participants were given
the consent form to review.
3.1.1.3. Ensuring valid informed consent. Recognizing the value of a col-
laborative approach to developing the informed consent document
(de Vries et al., 2011), the GSNESTT informed consent form was devel-
oped in an iterative fashion with input from stakeholders including re-
searchers at the collaborating institutions, and in accordance with
international best practice. With the assistance of a local geneticist
trained in research ethics and the conduct of genetics research in under-
represented communities, a genetics team was trained speciﬁcally to
obtain informed consent and collect samples at the individual level.
Training included using local analogies to explain complex terms;
collecting consent in various settings – from the clinic to under a tree
in a yard; and discussing complex ethical issues like incidental ﬁndings,
recontact, biobanking, and the limits of privacy and conﬁdentiality
(Chokshi et al., 2007; de Vries et al., 2011; Wright et al., 2013; Tindana
et al., 2012; McGuire et al., 2008).
Although not discussed in the literature, the GSNESTT team enlisted
a local holding aMasters level degree in clinical psychology as an added
safeguard to address issues related to the comprehension level of poten-
tial participants. This individual, who also received the study speciﬁc
training alongside the team, was selected to lead the GSNESTT
consenting group and helped to ensure that the team recognized verbal
and nonverbal cues indicating poor comprehension, possible
Table 3
Areas of the CIOMS Guidelines addressed in the GSNESTT.
CIOMS Guideline Addressed Not 
Addressed
Not 
applicable
Guideline 1: Ethical justification and scientific validity of biomedical 
research involving human beings
Guideline 2: Ethical review committees
Guideline 3: Ethical review of externally sponsored research
Guideline 4: Individual informed consent
Guideline 5: Obtaining informed consent: Essential information for 
prospective research subjects
Guideline 6: Obtaining informed consent: Obligations of sponsors 
and investigators
Guideline 7: Inducement to participate
Guideline 8: Benefits and risks of study participation
Guideline 9: Special limitations on risk when research 
involves individuals who are not capable of giving informed consent
Guideline 10: Research in populations and communities with limited 
resources
Guideline 11: Choice of control in clinical trials
Guideline 12: Equitable distribution of burdens and benefits in the 
selection of groups of subjects in research
Guideline 13: Research involving vulnerable persons
Guideline 14: Research involving children
Guideline 15: Research involving individuals who by reason of 
mental or behavioural disorders are not capable of giving adequately 
informed consent
Guideline 16: Women as research subjects
Guideline 17: Pregnant women as research participants.
Guideline 18: Safeguarding confidentiality
Guideline 19: Right of injured subjects to treatment and compensation
Guideline 20: Strengthening capacity for ethical and scientific 
review and biomedical research
Guideline 21: Ethical obligation of external sponsors to provide 
health-care services
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ipants felt unduly inﬂuenced or coerced to participate in the study.
3.1.1.4. Assuring the quality of the informed consent process. Tindana et al.
(2012) includes discussion on assuring the quality of the informed con-
sent process. The GSNESTT addressed this issue by undertaking an audit
of the informed consent process during the pilot phase of the study. For
the purpose of this audit a transdisciplinary team of observers was as-
sembled. This included members of the NESTT Sample Governance
Committee and NESTT Steering Committee. In addition, to ensure trans-
parency and independent review, other stakeholders were invited, in-
cluding a representative from the Ministry of Health, a representative
of the inter-religious organization, and a well-established bioethicist
from a regional public health agency.
The audit team visited the survey team in the clinic, and was asked
to document, on audit proforma, whether ethical standards and re-
quirements were being met, and whether the procedures employed in
the ﬁeld upheld best practices in the area, and were consistent with
those set out in the approved study protocols. Speciﬁcally, the team
was asked to ensure that: a) participants were being consentedadequately and free of coercion; b) participants comprehended what
they were consenting to; c) participants' (research subject) rights
were being upheld; and d) participant samples were being appropriate-
ly collected. They were also asked to document their observations re-
garding steps taken to ensure participant privacy and conﬁdentiality,
and the environment in which the study was taking place. The audit
team submitted a report, which indicated that no direct breach of par-
ticipants' rights was observed and that participants' samples appeared
to be appropriately collected. However, areas for improvement were
also noted, which were submitted in the form of recommendations to
the NESTT Steering Committee. Brieﬂy themain change included giving
the study participantsmore time to process the details and implications
of the study before consent was taken, and this change was adopted by
the survey team.
3.1.2. Regulating human genomics research
3.1.2.1. Acquiring necessary ethics approvals. From an ethical perspective,
perhaps themost challenging aspect of this study was ensuring that the
research was well-regulated given the absence of local policy. To begin,
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sential for theGenetics substudy to receive ethics approval from the col-
laborating academic institutions and the local Ministry of Health – an
approach consistent with Caulﬁeld et al. (2008), de Vries et al. (2011),
and Wright et al. (2013). In total, the study received ethics approvals
from 4 ethics committees located in 3 different countries, each with
their own standards and list of requirements. Notwithstanding the pro-
cedural delays and logistical challenges, meeting the requirements of
these multiple committees ensured that the proposed study met both
local and international standards in research ethics.
3.1.2.2. Regulating transfer of samples and data across borders. Additional-
ly, it was decided that a Materials Transfer Agreement (MTA) was criti-
cal to regulate the transfer of samples abroad (de Vries et al., 2011;
Wright et al., 2013). As a result, a three-way MTA was developed and
signed by the three collaborating universities: The University of the
West Indies, Duke University and Anglia Ruskin University. Key areas
addressed in this MTA included the purpose of transferring the mate-
rials to Duke University and limits of use, applicable laws regulating
the handling of the samples and privacy and conﬁdentiality of data.
3.1.2.3. Regulating secondary use of data. A Sample Governance Commit-
tee (SGC) was established to oversee the future use of, and access to,
DNA extracted from samples collected in this study (Chokshi et al.,
2006; Parker et al., 2009; Caulﬁeld et al., 2008; Wright et al., 2013;
Kaye et al., 2010). This diverse team comprisedmembers of all three ac-
ademic institutions, theMinistry of Health, and independent local scien-
tists. The principal duties of the SGC included advising on secondary
uses and analyses for the purposes of academic outputs.
An important role of the SGC was to ensure sample use in compli-
ance with the permissions received from the participants. To facilitate
this, a coded databasewas created containing information from consent
forms regarding varying limits of use thatwere agreed upon individual-
ly by each participant. Speciﬁcally, this database contained information
on whether permission was granted for DNA to be used for only NESTT
study research; for other research involving eye and cardiovascular
disease; or for inclusion in the Duke biobank, for general biomedical re-
search. The database also contained other information about participant
preference regarding 1) being informed about incidental ﬁndings; and
2) being re-contacted for future studies.
3.1.3. Protecting the interests of scientists in the host country
3.1.3.1. Capacity building in TT.Whenever international collaborative re-
search is conducted in lesser developed countries there is always a con-
cern that the interests of scientists in the host country should be
protected. To account for this, the GSNESTT included several efforts to
build capacity in the host country. For example, all local members of
the study team were provided with basic education in genetics and
trained to convey genetic information and identify ethical, legal and so-
cial issues associated with genetics/genomics research.
In addition several local professionalswere included in theGSNESTT.
Speciﬁcally, a local human geneticist was employed as a consultant to
the study and an individual trained in clinical psychologywas employed
to lead consenting efforts. Local scientists were selected to lead sub-
committees, including the Sample Governance Committee. It was also
agreed that local collaborating investigators would co-author publica-
tions arising from the study. Inspired partly by the GSNESTT, an article
was published highlighting the need to build capacity for genetics and
genomics research in TT and the wider region (Roach et al., 2015). Pro-
visionwas alsomade for local scientists, through application to the Sam-
ple Governance Committee, to have access to the de-identiﬁed data
generated through the GSNESTT for research.
Building on thework of theGSNESTT project, the local geneticistwas
hired by the local university to build a research ethics curriculum, train
healthcare students in the ethical, legal and social implications ofgenetics research, and serve on the University's research ethics commit-
tee. This expanded the curriculum and added expertise to the research
ethics committee at the university, and also reﬂected the university's
recognition of the importance of building capacity in this area.
3.2. Consistency with international guidelines
A summary of the areas of the International Ethical Guidelines for
Biomedical Research Involving Human Subjects herein referred to as
CIOMS (CIOMS, 2002) that was covered in the GSNESTT study is pre-
sented in Table 3. Brieﬂy, 19 of the 21 ethical guidelines included in
the CIOMS were considered. Of the remaining 2 guidelines, “Guideline
11: Choice of Clinical Trials”, was not considered because the GSNESTT
was not a clinical trial; and “Guideline 19: Right of injured subjects to
treatment and compensation”, was not considered because the dona-
tion of a saliva sample for the GSNESTT was considered to confer mini-
mal risk of causing injury. It must also be noted that in TT, public health
care that is free at the point of delivery is provided to all citizens by the
Ministry of Health who sponsored the research.
4. Discussion
In summary, eight key areas of concern were identiﬁed as requiring
special attention for human genetics and genomics research in TT:
1) fair selection of study participants, 2) community engagement and
sensitization; 3) ensuring valid informed consent; 4) assuring the qual-
ity of the informed consent process; 5) acquiring necessary ethics ap-
provals; 6) regulating the transfer of data across borders; 7) regulating
the secondary use of data; and 8) Capacity-building in TT. Using strate-
gies identiﬁed in the literature, combined with novel approaches and
responsiveness to challenges encountered in the ﬁeld, we were able to
develop a culturally appropriate, multifaceted strategy to address po-
tential ethical challenges in the GSNESTT.
Speciﬁcally, in addressing issues of fair selection of study partici-
pants we decided to exclude children as participants. Related to issues
of fair selection, community engagement and sensitization was viewed
as crucial to recruiting participants whomay be research-naïve. As a re-
sult an extensive community engagement and sensitization plan was
developedwhich took into account the culture and diversity of commu-
nities targeted. To ensure valid informed consent, several strategies
were used including the involvement of local expertise and training of
the consent team. Issues related to comprehension were further ad-
dressed by involving an individual trained in clinical psychology as a
member of the consenting team. Additionally, the quality of the in-
formed consent process was assured through an independent audit.
The study acquired ethics approvals from all institutions involved and
the local Ministry of Health, and issues related to the transfer and sec-
ondary use of samples and data were addressed through a legally
binding Materials Transfer Agreement and a Sample Governance
Committee, respectively. Finally as all international collaborative
research projects should seek to build capacity in the host country, sev-
eral mechanisms were put in place to protect the interests of scientists
in TT.
4.1. Unexpected challenges
Every researchproject faces unexpected challenges. One unexpected
challenge was the time required to develop and implement this ethical
framework, and to receive the necessary ethics committee approvals.
This resulted in a delayed start of the GSNESTT relative to the start
of the epidemiological survey. In the end, this delay affected the
GSNESTT participant recruitment process. A second unexpected chal-
lenge was the development of a negative public campaign, launched
by stakeholders opposed to the genomics research project. This aimed
to dissuade the population fromparticipating in both themain epidemi-
ological and genetics studies. The campaign utilized newspaper
14 A.N. Roach et al. / Applied & Translational Genomics 9 (2016) 6–14advertisements, letters to professional societies and other stakeholders,
including high level government ofﬁcials and administrators at all the
academic institutions involved. This campaign questioned the use of
public funds, the ethical framework used for the study, the involvement
of children in the study, and the creation of a biobankwith storage of tis-
sue abroad - the same ethical issues that were taken into consideration
in the development of the above plan. To date it is unclear what effect, if
any, this campaign may have had on the general perception of the eth-
ical acceptability of the GSNESTT.
5. Conclusion
The diversity of political, sociocultural and infrastructural factors
that exist in each countrymay impede the establishment of a single eth-
ical approach to international collaborative genetics/genomics research
that will be effective in all contexts. However, as the GSNESTT experi-
ence proves, drawing on the published experiences of other projects,
it is possible to identify key areas in HGR that require special attention
and then integrate several previously tested mechanisms to address
many ethical issues that may arise. Novel approaches integrated into
the GSNESTT include the use of a local trained in clinical psychology to
lead the informed consent process, and developing an audit protocol
to assure the quality and validity of the informed consent process. It is
critical that any framework developed also addresses key areas outlined
in international guidelines like the CIOMS. Care must also be taken at
every step to ensure that study protocols are sensitive to the culture
and terrain of each community or subgroup targeted within a country.
Community engagement and recruitment is a resource and labor-
intensive aspect of the project, and required creativity and ﬂexibility
to achieve successful implementation.
Our experience suggests that for research projects involving genetics
to be successful, ethical issues must be integrated into the design and
implementation of the project. The value and importance of identifying
and meaningfully engaging with all interested stakeholders, prior to a
major project, and throughout its evolution, cannot be overstated.
Failure to do so can lead to costly delays andmay potentially undermine
the viability of the research. Building on the GSNESTT, we recommend
that further investment is made to develop community education in
genetics and the implications of genetics research in Trinidad and
Tobago.
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